Heidi Splete

SAN DIEGO – Type 2 diabetes patients achieved greater blood sugar control with once-daily liraglutide injections than with other standard type 2 diabetes medications, according to the findings from a meta-analysis of seven phase III studies. The findings were presented April 14 at the annual meeting of the American Association of Clinical Endocrinologists.

"The progressive nature of type 2 diabetes makes it difficult for any single therapy to be effective long-term," said Dr. Robert Henry of the University of California, San Diego.

Liraglutide (Victoza) was approved by the Food and Drug Administration in January 2010 to treat type 2 diabetes in adults as an adjunct therapy to a healthy diet and exercise.

To further evaluate the impact of liraglutide on blood sugar control, Dr. Henry and his colleagues consolidated data from seven phase III clinical trials and divided the patients into five categories based on their baseline hemoglobin A_1c level: 7.5% or less (651 patients), 7.6%-8.0% (601 patients), 8.1%-8.5% (538 patients), 8.6%-9.0% (432 patients), and greater than 9.0% (607 patients).

The researchers reviewed the mean changes in HbA_1c from baseline to 26 weeks of treatment. Overall, mean hemoglobin A_1c reductions with a once-daily, 1.8-mg dose of liraglutide were greater than the reductions achieved with standard regimens involving exenatide, insulin glargine, glimepiride, rosiglitazone, or sitagliptin.

In particular, HbA_1c levels were significantly reduced in patients with a baseline HbA_1c of 7.5% or less in the liraglutide group compared with all other groups. The mean reductions in HbA_1c for patients on liraglutide ranged from 0.7% in the 7.5% or less category to 1.8% in the greater than 9.0% category. The next best mean reduction in HbA_1c was seen among patients taking two other injectable therapies: insulin glargine and exenatide. Reductions in HbA_1c in patients taking insulin glargine ranged from 0.3% to 1.5%, and HbA_1c reductions in those taking exenatide ranged from 0.4% to 1.3%.

Patients taking sulfonylureas, sitagliptin, or thiazolidinediones showed less improvement from baseline than did patients taking the injectables. The average reduction in patients taking sitagliptin ranged from 0.0% to 1.1%. The average reduction with sulfonylureas ranged from 0.4% to 1.4%, and the average reduction with thiazolidinediones ranged from 0.4% to 0.8%.

Among 348 patients in the liraglutide group with baseline HbA_1c levels of 7.5% or less, 216 (63%) reached the AACE-recommended HbA_1c target of 6.5% or less, compared with less than half (20%-49%) of patients with a baseline HbA_1c of 7.5% or less in the other groups, Dr. Henry noted.

Among 333 patients in the liraglutide group with HbA_1c levels greater than 9.0%, 33 (10%) reached the 6.5% or less target, compared with 4 (12%) of 34 patients in the insulin glargine group and 0%-5% of patients in the other groups.

The study was limited by the use of mean data, which does not account for individual variability, but the results suggest that liraglutide was effective at reducing HbA_1c throughout the baseline HbA_1c spectrum, Dr. Henry said.

The study was sponsored by Novo Nordisk, which manufactures liraglutide. Dr. Henry has received research support from multiple pharmaceutical companies, including Amylin Pharmaceuticals, AstraZeneca, and Novartis. He has served as an adviser or consultant for, and has received consulting fees from, several companies, including Amylin, Eli Lilly, and Novo Nordisk.

SAN DIEGO – Type 2 diabetes patients achieved greater blood sugar control with once-daily liraglutide injections than with other standard type 2 diabetes medications, according to the findings from a meta-analysis of seven phase III studies. The findings were presented April 14 at the annual meeting of the American Association of Clinical Endocrinologists.

"The progressive nature of type 2 diabetes makes it difficult for any single therapy to be effective long-term," said Dr. Robert Henry of the University of California, San Diego.

Liraglutide (Victoza) was approved by the Food and Drug Administration in January 2010 to treat type 2 diabetes in adults as an adjunct therapy to a healthy diet and exercise.

To further evaluate the impact of liraglutide on blood sugar control, Dr. Henry and his colleagues consolidated data from seven phase III clinical trials and divided the patients into five categories based on their baseline hemoglobin A_1c level: 7.5% or less (651 patients), 7.6%-8.0% (601 patients), 8.1%-8.5% (538 patients), 8.6%-9.0% (432 patients), and greater than 9.0% (607 patients).

The researchers reviewed the mean changes in HbA_1c from baseline to 26 weeks of treatment. Overall, mean hemoglobin A_1c reductions with a once-daily, 1.8-mg dose of liraglutide were greater than the reductions achieved with standard regimens involving exenatide, insulin glargine, glimepiride, rosiglitazone, or sitagliptin.

In particular, HbA_1c levels were significantly reduced in patients with a baseline HbA_1c of 7.5% or less in the liraglutide group compared with all other groups. The mean reductions in HbA_1c for patients on liraglutide ranged from 0.7% in the 7.5% or less category to 1.8% in the greater than 9.0% category. The next best mean reduction in HbA_1c was seen among patients taking two other injectable therapies: insulin glargine and exenatide. Reductions in HbA_1c in patients taking insulin glargine ranged from 0.3% to 1.5%, and HbA_1c reductions in those taking exenatide ranged from 0.4% to 1.3%.

Patients taking sulfonylureas, sitagliptin, or thiazolidinediones showed less improvement from baseline than did patients taking the injectables. The average reduction in patients taking sitagliptin ranged from 0.0% to 1.1%. The average reduction with sulfonylureas ranged from 0.4% to 1.4%, and the average reduction with thiazolidinediones ranged from 0.4% to 0.8%.

Among 348 patients in the liraglutide group with baseline HbA_1c levels of 7.5% or less, 216 (63%) reached the AACE-recommended HbA_1c target of 6.5% or less, compared with less than half (20%-49%) of patients with a baseline HbA_1c of 7.5% or less in the other groups, Dr. Henry noted.

Among 333 patients in the liraglutide group with HbA_1c levels greater than 9.0%, 33 (10%) reached the 6.5% or less target, compared with 4 (12%) of 34 patients in the insulin glargine group and 0%-5% of patients in the other groups.

The study was limited by the use of mean data, which does not account for individual variability, but the results suggest that liraglutide was effective at reducing HbA_1c throughout the baseline HbA_1c spectrum, Dr. Henry said.

The study was sponsored by Novo Nordisk, which manufactures liraglutide. Dr. Henry has received research support from multiple pharmaceutical companies, including Amylin Pharmaceuticals, AstraZeneca, and Novartis. He has served as an adviser or consultant for, and has received consulting fees from, several companies, including Amylin, Eli Lilly, and Novo Nordisk.

SAN DIEGO – Type 2 diabetes patients achieved greater blood sugar control with once-daily liraglutide injections than with other standard type 2 diabetes medications, according to the findings from a meta-analysis of seven phase III studies. The findings were presented April 14 at the annual meeting of the American Association of Clinical Endocrinologists.

"The progressive nature of type 2 diabetes makes it difficult for any single therapy to be effective long-term," said Dr. Robert Henry of the University of California, San Diego.

Liraglutide (Victoza) was approved by the Food and Drug Administration in January 2010 to treat type 2 diabetes in adults as an adjunct therapy to a healthy diet and exercise.

To further evaluate the impact of liraglutide on blood sugar control, Dr. Henry and his colleagues consolidated data from seven phase III clinical trials and divided the patients into five categories based on their baseline hemoglobin A_1c level: 7.5% or less (651 patients), 7.6%-8.0% (601 patients), 8.1%-8.5% (538 patients), 8.6%-9.0% (432 patients), and greater than 9.0% (607 patients).

The researchers reviewed the mean changes in HbA_1c from baseline to 26 weeks of treatment. Overall, mean hemoglobin A_1c reductions with a once-daily, 1.8-mg dose of liraglutide were greater than the reductions achieved with standard regimens involving exenatide, insulin glargine, glimepiride, rosiglitazone, or sitagliptin.

In particular, HbA_1c levels were significantly reduced in patients with a baseline HbA_1c of 7.5% or less in the liraglutide group compared with all other groups. The mean reductions in HbA_1c for patients on liraglutide ranged from 0.7% in the 7.5% or less category to 1.8% in the greater than 9.0% category. The next best mean reduction in HbA_1c was seen among patients taking two other injectable therapies: insulin glargine and exenatide. Reductions in HbA_1c in patients taking insulin glargine ranged from 0.3% to 1.5%, and HbA_1c reductions in those taking exenatide ranged from 0.4% to 1.3%.

Patients taking sulfonylureas, sitagliptin, or thiazolidinediones showed less improvement from baseline than did patients taking the injectables. The average reduction in patients taking sitagliptin ranged from 0.0% to 1.1%. The average reduction with sulfonylureas ranged from 0.4% to 1.4%, and the average reduction with thiazolidinediones ranged from 0.4% to 0.8%.

Among 348 patients in the liraglutide group with baseline HbA_1c levels of 7.5% or less, 216 (63%) reached the AACE-recommended HbA_1c target of 6.5% or less, compared with less than half (20%-49%) of patients with a baseline HbA_1c of 7.5% or less in the other groups, Dr. Henry noted.

Among 333 patients in the liraglutide group with HbA_1c levels greater than 9.0%, 33 (10%) reached the 6.5% or less target, compared with 4 (12%) of 34 patients in the insulin glargine group and 0%-5% of patients in the other groups.

The study was limited by the use of mean data, which does not account for individual variability, but the results suggest that liraglutide was effective at reducing HbA_1c throughout the baseline HbA_1c spectrum, Dr. Henry said.

The study was sponsored by Novo Nordisk, which manufactures liraglutide. Dr. Henry has received research support from multiple pharmaceutical companies, including Amylin Pharmaceuticals, AstraZeneca, and Novartis. He has served as an adviser or consultant for, and has received consulting fees from, several companies, including Amylin, Eli Lilly, and Novo Nordisk.

SAN FRANCISCO – Children with recurrent, severe virus-induced wheezing during their first 3 years of life had significantly reduced prebronchodilator lung function at school age, compared with children with no history of wheezing, but no differences were seen on tests of postbronchodilator lung function, based on data from 215 children.

Previous studies have shown that early childhood is a vulnerable time for the development of lung function, and recurrent wheezing can be a major risk factor for reduced lung function when children reach school age, said Dr. Daniel Jackson of the University of Wisconsin, Madison, and his colleagues.

"This is particularly important because loss of lung function is associated with morbidity and limitation due to asthma," Dr. Jackson said in an interview.

The researchers reviewed data from the Childhood Origins of Asthma (COAST) study, a prospective study of children at increased risk for allergies or asthma. They divided the children into four groups according to their wheezing history. The groups consisted of 101 children with no wheezing, 69 children with wheezing who received no oral corticosteroids, 23 children who received corticosteroids with one episode of wheezing, and 22 children who received corticosteroids with two or more episodes of wheezing. Pre- and postbronchodilator spirometry was performed each year to check lung function and compare lung volume among the groups, according to the researchers’ poster, which was presented at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

Overall, prebronchodilator forced expiratory volume in 0.5- and 1-second (FEV_0.5 and FEV₁) measures obtained at age 5-8 years were significantly lower in children with histories of multiple wheezing episodes treated with oral corticosteroids, compared with each of the other groups, after the investigators controlled for factors including asthma, age, sex, height, weight, race, and smoke exposure. The children with two or more wheezing episodes treated with oral corticosteroids had an average FEV₁ of 1.26 L, compared with 1.37 L in children with no episodes of wheezing, 1.34 L in children who had wheezing without oral corticosteroid treatment, and 1.38 L in children who had wheezing with one oral corticosteroid treatment.

However, postbronchodilator measures taken at 6-8 years were not significantly different in children with repeated wheezing episodes, compared with children with fewer or no wheezing episodes.

The findings suggest that reduced lung function in school-aged children at high risk for asthma is at least partially reversible, the researchers noted. "Whether these severe wheezing episodes caused progressive lung function or were due to low baseline lung function is not known," they wrote. But the results also suggest that preventing severe wheezing in early childhood could reduce later problems caused by a loss of lung function, and new therapeutic strategies are needed to prevent virus-induced wheezing in high-risk children, they added.

The study was supported by grants from the National Institutes of Health. Dr. Jackson said he had no relevant financial disclosures.

SAN FRANCISCO – Children with recurrent, severe virus-induced wheezing during their first 3 years of life had significantly reduced prebronchodilator lung function at school age, compared with children with no history of wheezing, but no differences were seen on tests of postbronchodilator lung function, based on data from 215 children.

Previous studies have shown that early childhood is a vulnerable time for the development of lung function, and recurrent wheezing can be a major risk factor for reduced lung function when children reach school age, said Dr. Daniel Jackson of the University of Wisconsin, Madison, and his colleagues.

"This is particularly important because loss of lung function is associated with morbidity and limitation due to asthma," Dr. Jackson said in an interview.

The researchers reviewed data from the Childhood Origins of Asthma (COAST) study, a prospective study of children at increased risk for allergies or asthma. They divided the children into four groups according to their wheezing history. The groups consisted of 101 children with no wheezing, 69 children with wheezing who received no oral corticosteroids, 23 children who received corticosteroids with one episode of wheezing, and 22 children who received corticosteroids with two or more episodes of wheezing. Pre- and postbronchodilator spirometry was performed each year to check lung function and compare lung volume among the groups, according to the researchers’ poster, which was presented at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

Overall, prebronchodilator forced expiratory volume in 0.5- and 1-second (FEV_0.5 and FEV₁) measures obtained at age 5-8 years were significantly lower in children with histories of multiple wheezing episodes treated with oral corticosteroids, compared with each of the other groups, after the investigators controlled for factors including asthma, age, sex, height, weight, race, and smoke exposure. The children with two or more wheezing episodes treated with oral corticosteroids had an average FEV₁ of 1.26 L, compared with 1.37 L in children with no episodes of wheezing, 1.34 L in children who had wheezing without oral corticosteroid treatment, and 1.38 L in children who had wheezing with one oral corticosteroid treatment.

However, postbronchodilator measures taken at 6-8 years were not significantly different in children with repeated wheezing episodes, compared with children with fewer or no wheezing episodes.

The findings suggest that reduced lung function in school-aged children at high risk for asthma is at least partially reversible, the researchers noted. "Whether these severe wheezing episodes caused progressive lung function or were due to low baseline lung function is not known," they wrote. But the results also suggest that preventing severe wheezing in early childhood could reduce later problems caused by a loss of lung function, and new therapeutic strategies are needed to prevent virus-induced wheezing in high-risk children, they added.

The study was supported by grants from the National Institutes of Health. Dr. Jackson said he had no relevant financial disclosures.

SAN FRANCISCO – Children with recurrent, severe virus-induced wheezing during their first 3 years of life had significantly reduced prebronchodilator lung function at school age, compared with children with no history of wheezing, but no differences were seen on tests of postbronchodilator lung function, based on data from 215 children.

Previous studies have shown that early childhood is a vulnerable time for the development of lung function, and recurrent wheezing can be a major risk factor for reduced lung function when children reach school age, said Dr. Daniel Jackson of the University of Wisconsin, Madison, and his colleagues.

"This is particularly important because loss of lung function is associated with morbidity and limitation due to asthma," Dr. Jackson said in an interview.

The researchers reviewed data from the Childhood Origins of Asthma (COAST) study, a prospective study of children at increased risk for allergies or asthma. They divided the children into four groups according to their wheezing history. The groups consisted of 101 children with no wheezing, 69 children with wheezing who received no oral corticosteroids, 23 children who received corticosteroids with one episode of wheezing, and 22 children who received corticosteroids with two or more episodes of wheezing. Pre- and postbronchodilator spirometry was performed each year to check lung function and compare lung volume among the groups, according to the researchers’ poster, which was presented at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

Overall, prebronchodilator forced expiratory volume in 0.5- and 1-second (FEV_0.5 and FEV₁) measures obtained at age 5-8 years were significantly lower in children with histories of multiple wheezing episodes treated with oral corticosteroids, compared with each of the other groups, after the investigators controlled for factors including asthma, age, sex, height, weight, race, and smoke exposure. The children with two or more wheezing episodes treated with oral corticosteroids had an average FEV₁ of 1.26 L, compared with 1.37 L in children with no episodes of wheezing, 1.34 L in children who had wheezing without oral corticosteroid treatment, and 1.38 L in children who had wheezing with one oral corticosteroid treatment.

However, postbronchodilator measures taken at 6-8 years were not significantly different in children with repeated wheezing episodes, compared with children with fewer or no wheezing episodes.

The findings suggest that reduced lung function in school-aged children at high risk for asthma is at least partially reversible, the researchers noted. "Whether these severe wheezing episodes caused progressive lung function or were due to low baseline lung function is not known," they wrote. But the results also suggest that preventing severe wheezing in early childhood could reduce later problems caused by a loss of lung function, and new therapeutic strategies are needed to prevent virus-induced wheezing in high-risk children, they added.

The study was supported by grants from the National Institutes of Health. Dr. Jackson said he had no relevant financial disclosures.

SAN FRANCISCO – Children with recurrent, severe virus-induced wheezing during their first 3 years of life had significantly reduced prebronchodilator lung function at school age, compared with children with no history of wheezing, but no differences were seen on tests of postbronchodilator lung function, based on data from 215 children.

Previous studies have shown that early childhood is a vulnerable time for the development of lung function, and recurrent wheezing can be a major risk factor for reduced lung function when children reach school age, said Dr. Daniel Jackson of the University of Wisconsin, Madison, and his colleagues.

"This is particularly important because loss of lung function is associated with morbidity and limitation due to asthma," Dr. Jackson said in an interview.

The researchers reviewed data from the Childhood Origins of Asthma (COAST) study, a prospective study of children at increased risk for allergies or asthma. They divided the children into four groups according to their wheezing history. The groups consisted of 101 children with no wheezing, 69 children with wheezing who received no oral corticosteroids, 23 children who received corticosteroids with one episode of wheezing, and 22 children who received corticosteroids with two or more episodes of wheezing. Pre- and postbronchodilator spirometry was performed each year to check lung function and compare lung volume among the groups, according to the researchers’ poster, which was presented at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

Overall, prebronchodilator forced expiratory volume in 0.5- and 1-second (FEV_0.5 and FEV₁) measures obtained at age 5-8 years were significantly lower in children with histories of multiple wheezing episodes treated with oral corticosteroids, compared with each of the other groups, after the investigators controlled for factors including asthma, age, sex, height, weight, race, and smoke exposure. The children with two or more wheezing episodes treated with oral corticosteroids had an average FEV₁ of 1.26 L, compared with 1.37 L in children with no episodes of wheezing, 1.34 L in children who had wheezing without oral corticosteroid treatment, and 1.38 L in children who had wheezing with one oral corticosteroid treatment.

However, postbronchodilator measures taken at 6-8 years were not significantly different in children with repeated wheezing episodes, compared with children with fewer or no wheezing episodes.

The findings suggest that reduced lung function in school-aged children at high risk for asthma is at least partially reversible, the researchers noted. "Whether these severe wheezing episodes caused progressive lung function or were due to low baseline lung function is not known," they wrote. But the results also suggest that preventing severe wheezing in early childhood could reduce later problems caused by a loss of lung function, and new therapeutic strategies are needed to prevent virus-induced wheezing in high-risk children, they added.

The study was supported by grants from the National Institutes of Health. Dr. Jackson said he had no relevant financial disclosures.

SAN FRANCISCO – Children with recurrent, severe virus-induced wheezing during their first 3 years of life had significantly reduced prebronchodilator lung function at school age, compared with children with no history of wheezing, but no differences were seen on tests of postbronchodilator lung function, based on data from 215 children.

Previous studies have shown that early childhood is a vulnerable time for the development of lung function, and recurrent wheezing can be a major risk factor for reduced lung function when children reach school age, said Dr. Daniel Jackson of the University of Wisconsin, Madison, and his colleagues.

"This is particularly important because loss of lung function is associated with morbidity and limitation due to asthma," Dr. Jackson said in an interview.

The researchers reviewed data from the Childhood Origins of Asthma (COAST) study, a prospective study of children at increased risk for allergies or asthma. They divided the children into four groups according to their wheezing history. The groups consisted of 101 children with no wheezing, 69 children with wheezing who received no oral corticosteroids, 23 children who received corticosteroids with one episode of wheezing, and 22 children who received corticosteroids with two or more episodes of wheezing. Pre- and postbronchodilator spirometry was performed each year to check lung function and compare lung volume among the groups, according to the researchers’ poster, which was presented at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

Overall, prebronchodilator forced expiratory volume in 0.5- and 1-second (FEV_0.5 and FEV₁) measures obtained at age 5-8 years were significantly lower in children with histories of multiple wheezing episodes treated with oral corticosteroids, compared with each of the other groups, after the investigators controlled for factors including asthma, age, sex, height, weight, race, and smoke exposure. The children with two or more wheezing episodes treated with oral corticosteroids had an average FEV₁ of 1.26 L, compared with 1.37 L in children with no episodes of wheezing, 1.34 L in children who had wheezing without oral corticosteroid treatment, and 1.38 L in children who had wheezing with one oral corticosteroid treatment.

However, postbronchodilator measures taken at 6-8 years were not significantly different in children with repeated wheezing episodes, compared with children with fewer or no wheezing episodes.

The findings suggest that reduced lung function in school-aged children at high risk for asthma is at least partially reversible, the researchers noted. "Whether these severe wheezing episodes caused progressive lung function or were due to low baseline lung function is not known," they wrote. But the results also suggest that preventing severe wheezing in early childhood could reduce later problems caused by a loss of lung function, and new therapeutic strategies are needed to prevent virus-induced wheezing in high-risk children, they added.

The study was supported by grants from the National Institutes of Health. Dr. Jackson said he had no relevant financial disclosures.

SAN FRANCISCO – Children with recurrent, severe virus-induced wheezing during their first 3 years of life had significantly reduced prebronchodilator lung function at school age, compared with children with no history of wheezing, but no differences were seen on tests of postbronchodilator lung function, based on data from 215 children.

Previous studies have shown that early childhood is a vulnerable time for the development of lung function, and recurrent wheezing can be a major risk factor for reduced lung function when children reach school age, said Dr. Daniel Jackson of the University of Wisconsin, Madison, and his colleagues.

"This is particularly important because loss of lung function is associated with morbidity and limitation due to asthma," Dr. Jackson said in an interview.

The researchers reviewed data from the Childhood Origins of Asthma (COAST) study, a prospective study of children at increased risk for allergies or asthma. They divided the children into four groups according to their wheezing history. The groups consisted of 101 children with no wheezing, 69 children with wheezing who received no oral corticosteroids, 23 children who received corticosteroids with one episode of wheezing, and 22 children who received corticosteroids with two or more episodes of wheezing. Pre- and postbronchodilator spirometry was performed each year to check lung function and compare lung volume among the groups, according to the researchers’ poster, which was presented at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

Overall, prebronchodilator forced expiratory volume in 0.5- and 1-second (FEV_0.5 and FEV₁) measures obtained at age 5-8 years were significantly lower in children with histories of multiple wheezing episodes treated with oral corticosteroids, compared with each of the other groups, after the investigators controlled for factors including asthma, age, sex, height, weight, race, and smoke exposure. The children with two or more wheezing episodes treated with oral corticosteroids had an average FEV₁ of 1.26 L, compared with 1.37 L in children with no episodes of wheezing, 1.34 L in children who had wheezing without oral corticosteroid treatment, and 1.38 L in children who had wheezing with one oral corticosteroid treatment.

However, postbronchodilator measures taken at 6-8 years were not significantly different in children with repeated wheezing episodes, compared with children with fewer or no wheezing episodes.

The findings suggest that reduced lung function in school-aged children at high risk for asthma is at least partially reversible, the researchers noted. "Whether these severe wheezing episodes caused progressive lung function or were due to low baseline lung function is not known," they wrote. But the results also suggest that preventing severe wheezing in early childhood could reduce later problems caused by a loss of lung function, and new therapeutic strategies are needed to prevent virus-induced wheezing in high-risk children, they added.

The study was supported by grants from the National Institutes of Health. Dr. Jackson said he had no relevant financial disclosures.

NATIONAL HARBOR, MD. – Topical diclofenac sodium 1% gel was as well tolerated as placebo, based on data from 1,426 patients with knee osteoarthritis and 783 patients with hand osteoarthritis.

Findings from previous studies have shown that diclofenac sodium 1% gel (DSG) is effective in treating knee and hand osteoarthritis (OA), but safety data were limited, said Dr. John H. Peniston of Feasterville (Pa.) Family Health Clinic.

In this pooled analysis, the researchers reviewed data from patients aged 35 years and older with knee OA and aged 40 years and older with hand OA. The findings were presented in a poster at the annual meeting of the American Academy of Pain Medicine.

In the group with knee OA, 721 patients were randomized to DSG and 705 to a placebo gel. The most common adverse events were application site related; these occurred in 406 (56.3%) of the DSG patients and 340 (48.2%) of the placebo patients. The incidence of gastrointestinal, cardiovascular, hepatic, or renal adverse events (AEs) was similar between the two groups. The only serious AE potentially related to treatment was a deep-vein thrombosis and pulmonary embolism that developed in an 80-year-old woman with multiple cardiovascular–risk factors, the researchers noted. The most common treatment-emergent AE was headache, reported in approximately 15% of patients in each group.

In the group with hand OA, 400 patients were randomized to DSG and 383 to a placebo gel. Application site events were the most common AEs, occurring in 163 (40.8%) of the DSG patients and 139 (36.3%) of the placebo patients. Rates of cardiovascular, gastrointestinal, renal, and hepatic AEs were similar between the groups. Treatment-related gastrointestinal events occurred in two patients in the DSG group and one in the placebo group. None of the cardiovascular or serious AEs in either group were considered treatment-related, the researchers wrote. However, two patients with hand OA in both the active treatment and placebo groups experienced liver-enzyme elevation to three times the upper limit of normal. The most common treatment-emergent AE was headache, reported by 9% of patients in the DSG group and 10% of the placebo group.

"In general, adverse events with diclofenac sodium were mild and resolved without the need for additional treatment, consistent with a favorable tolerability profile," the researchers said.

The clinical trials for DSG were funded by Novartis, and this post hoc analysis was funded by Endo Pharmaceuticals. Dr. Peniston said he had no financial conflicts to disclose, but several study coauthors were employed by either Novartis or Endo.

NATIONAL HARBOR, MD. – Topical diclofenac sodium 1% gel was as well tolerated as placebo, based on data from 1,426 patients with knee osteoarthritis and 783 patients with hand osteoarthritis.

Findings from previous studies have shown that diclofenac sodium 1% gel (DSG) is effective in treating knee and hand osteoarthritis (OA), but safety data were limited, said Dr. John H. Peniston of Feasterville (Pa.) Family Health Clinic.

In this pooled analysis, the researchers reviewed data from patients aged 35 years and older with knee OA and aged 40 years and older with hand OA. The findings were presented in a poster at the annual meeting of the American Academy of Pain Medicine.

In the group with knee OA, 721 patients were randomized to DSG and 705 to a placebo gel. The most common adverse events were application site related; these occurred in 406 (56.3%) of the DSG patients and 340 (48.2%) of the placebo patients. The incidence of gastrointestinal, cardiovascular, hepatic, or renal adverse events (AEs) was similar between the two groups. The only serious AE potentially related to treatment was a deep-vein thrombosis and pulmonary embolism that developed in an 80-year-old woman with multiple cardiovascular–risk factors, the researchers noted. The most common treatment-emergent AE was headache, reported in approximately 15% of patients in each group.

In the group with hand OA, 400 patients were randomized to DSG and 383 to a placebo gel. Application site events were the most common AEs, occurring in 163 (40.8%) of the DSG patients and 139 (36.3%) of the placebo patients. Rates of cardiovascular, gastrointestinal, renal, and hepatic AEs were similar between the groups. Treatment-related gastrointestinal events occurred in two patients in the DSG group and one in the placebo group. None of the cardiovascular or serious AEs in either group were considered treatment-related, the researchers wrote. However, two patients with hand OA in both the active treatment and placebo groups experienced liver-enzyme elevation to three times the upper limit of normal. The most common treatment-emergent AE was headache, reported by 9% of patients in the DSG group and 10% of the placebo group.

"In general, adverse events with diclofenac sodium were mild and resolved without the need for additional treatment, consistent with a favorable tolerability profile," the researchers said.

The clinical trials for DSG were funded by Novartis, and this post hoc analysis was funded by Endo Pharmaceuticals. Dr. Peniston said he had no financial conflicts to disclose, but several study coauthors were employed by either Novartis or Endo.

NATIONAL HARBOR, MD. – Topical diclofenac sodium 1% gel was as well tolerated as placebo, based on data from 1,426 patients with knee osteoarthritis and 783 patients with hand osteoarthritis.

Findings from previous studies have shown that diclofenac sodium 1% gel (DSG) is effective in treating knee and hand osteoarthritis (OA), but safety data were limited, said Dr. John H. Peniston of Feasterville (Pa.) Family Health Clinic.

In this pooled analysis, the researchers reviewed data from patients aged 35 years and older with knee OA and aged 40 years and older with hand OA. The findings were presented in a poster at the annual meeting of the American Academy of Pain Medicine.

In the group with knee OA, 721 patients were randomized to DSG and 705 to a placebo gel. The most common adverse events were application site related; these occurred in 406 (56.3%) of the DSG patients and 340 (48.2%) of the placebo patients. The incidence of gastrointestinal, cardiovascular, hepatic, or renal adverse events (AEs) was similar between the two groups. The only serious AE potentially related to treatment was a deep-vein thrombosis and pulmonary embolism that developed in an 80-year-old woman with multiple cardiovascular–risk factors, the researchers noted. The most common treatment-emergent AE was headache, reported in approximately 15% of patients in each group.

In the group with hand OA, 400 patients were randomized to DSG and 383 to a placebo gel. Application site events were the most common AEs, occurring in 163 (40.8%) of the DSG patients and 139 (36.3%) of the placebo patients. Rates of cardiovascular, gastrointestinal, renal, and hepatic AEs were similar between the groups. Treatment-related gastrointestinal events occurred in two patients in the DSG group and one in the placebo group. None of the cardiovascular or serious AEs in either group were considered treatment-related, the researchers wrote. However, two patients with hand OA in both the active treatment and placebo groups experienced liver-enzyme elevation to three times the upper limit of normal. The most common treatment-emergent AE was headache, reported by 9% of patients in the DSG group and 10% of the placebo group.

"In general, adverse events with diclofenac sodium were mild and resolved without the need for additional treatment, consistent with a favorable tolerability profile," the researchers said.

The clinical trials for DSG were funded by Novartis, and this post hoc analysis was funded by Endo Pharmaceuticals. Dr. Peniston said he had no financial conflicts to disclose, but several study coauthors were employed by either Novartis or Endo.

NATIONAL HARBOR, MD. – Topical diclofenac sodium 1% gel was as well tolerated as placebo, based on data from 1,426 patients with knee osteoarthritis and 783 patients with hand osteoarthritis.

Findings from previous studies have shown that diclofenac sodium 1% gel (DSG) is effective in treating knee and hand osteoarthritis (OA), but safety data were limited, said Dr. John H. Peniston of Feasterville (Pa.) Family Health Clinic.

In this pooled analysis, the researchers reviewed data from patients aged 35 years and older with knee OA and aged 40 years and older with hand OA. The findings were presented in a poster at the annual meeting of the American Academy of Pain Medicine.

In the group with knee OA, 721 patients were randomized to DSG and 705 to a placebo gel. The most common adverse events were application site related; these occurred in 406 (56.3%) of the DSG patients and 340 (48.2%) of the placebo patients. The incidence of gastrointestinal, cardiovascular, hepatic, or renal adverse events (AEs) was similar between the two groups. The only serious AE potentially related to treatment was a deep-vein thrombosis and pulmonary embolism that developed in an 80-year-old woman with multiple cardiovascular–risk factors, the researchers noted. The most common treatment-emergent AE was headache, reported in approximately 15% of patients in each group.

In the group with hand OA, 400 patients were randomized to DSG and 383 to a placebo gel. Application site events were the most common AEs, occurring in 163 (40.8%) of the DSG patients and 139 (36.3%) of the placebo patients. Rates of cardiovascular, gastrointestinal, renal, and hepatic AEs were similar between the groups. Treatment-related gastrointestinal events occurred in two patients in the DSG group and one in the placebo group. None of the cardiovascular or serious AEs in either group were considered treatment-related, the researchers wrote. However, two patients with hand OA in both the active treatment and placebo groups experienced liver-enzyme elevation to three times the upper limit of normal. The most common treatment-emergent AE was headache, reported by 9% of patients in the DSG group and 10% of the placebo group.

"In general, adverse events with diclofenac sodium were mild and resolved without the need for additional treatment, consistent with a favorable tolerability profile," the researchers said.

The clinical trials for DSG were funded by Novartis, and this post hoc analysis was funded by Endo Pharmaceuticals. Dr. Peniston said he had no financial conflicts to disclose, but several study coauthors were employed by either Novartis or Endo.

NATIONAL HARBOR, MD. – Topical diclofenac sodium 1% gel was as well tolerated as placebo, based on data from 1,426 patients with knee osteoarthritis and 783 patients with hand osteoarthritis.

Findings from previous studies have shown that diclofenac sodium 1% gel (DSG) is effective in treating knee and hand osteoarthritis (OA), but safety data were limited, said Dr. John H. Peniston of Feasterville (Pa.) Family Health Clinic.

In this pooled analysis, the researchers reviewed data from patients aged 35 years and older with knee OA and aged 40 years and older with hand OA. The findings were presented in a poster at the annual meeting of the American Academy of Pain Medicine.

In the group with knee OA, 721 patients were randomized to DSG and 705 to a placebo gel. The most common adverse events were application site related; these occurred in 406 (56.3%) of the DSG patients and 340 (48.2%) of the placebo patients. The incidence of gastrointestinal, cardiovascular, hepatic, or renal adverse events (AEs) was similar between the two groups. The only serious AE potentially related to treatment was a deep-vein thrombosis and pulmonary embolism that developed in an 80-year-old woman with multiple cardiovascular–risk factors, the researchers noted. The most common treatment-emergent AE was headache, reported in approximately 15% of patients in each group.

In the group with hand OA, 400 patients were randomized to DSG and 383 to a placebo gel. Application site events were the most common AEs, occurring in 163 (40.8%) of the DSG patients and 139 (36.3%) of the placebo patients. Rates of cardiovascular, gastrointestinal, renal, and hepatic AEs were similar between the groups. Treatment-related gastrointestinal events occurred in two patients in the DSG group and one in the placebo group. None of the cardiovascular or serious AEs in either group were considered treatment-related, the researchers wrote. However, two patients with hand OA in both the active treatment and placebo groups experienced liver-enzyme elevation to three times the upper limit of normal. The most common treatment-emergent AE was headache, reported by 9% of patients in the DSG group and 10% of the placebo group.

"In general, adverse events with diclofenac sodium were mild and resolved without the need for additional treatment, consistent with a favorable tolerability profile," the researchers said.

The clinical trials for DSG were funded by Novartis, and this post hoc analysis was funded by Endo Pharmaceuticals. Dr. Peniston said he had no financial conflicts to disclose, but several study coauthors were employed by either Novartis or Endo.

NATIONAL HARBOR, MD. – Topical diclofenac sodium 1% gel was as well tolerated as placebo, based on data from 1,426 patients with knee osteoarthritis and 783 patients with hand osteoarthritis.

Findings from previous studies have shown that diclofenac sodium 1% gel (DSG) is effective in treating knee and hand osteoarthritis (OA), but safety data were limited, said Dr. John H. Peniston of Feasterville (Pa.) Family Health Clinic.

In this pooled analysis, the researchers reviewed data from patients aged 35 years and older with knee OA and aged 40 years and older with hand OA. The findings were presented in a poster at the annual meeting of the American Academy of Pain Medicine.

In the group with knee OA, 721 patients were randomized to DSG and 705 to a placebo gel. The most common adverse events were application site related; these occurred in 406 (56.3%) of the DSG patients and 340 (48.2%) of the placebo patients. The incidence of gastrointestinal, cardiovascular, hepatic, or renal adverse events (AEs) was similar between the two groups. The only serious AE potentially related to treatment was a deep-vein thrombosis and pulmonary embolism that developed in an 80-year-old woman with multiple cardiovascular–risk factors, the researchers noted. The most common treatment-emergent AE was headache, reported in approximately 15% of patients in each group.

In the group with hand OA, 400 patients were randomized to DSG and 383 to a placebo gel. Application site events were the most common AEs, occurring in 163 (40.8%) of the DSG patients and 139 (36.3%) of the placebo patients. Rates of cardiovascular, gastrointestinal, renal, and hepatic AEs were similar between the groups. Treatment-related gastrointestinal events occurred in two patients in the DSG group and one in the placebo group. None of the cardiovascular or serious AEs in either group were considered treatment-related, the researchers wrote. However, two patients with hand OA in both the active treatment and placebo groups experienced liver-enzyme elevation to three times the upper limit of normal. The most common treatment-emergent AE was headache, reported by 9% of patients in the DSG group and 10% of the placebo group.

"In general, adverse events with diclofenac sodium were mild and resolved without the need for additional treatment, consistent with a favorable tolerability profile," the researchers said.

The clinical trials for DSG were funded by Novartis, and this post hoc analysis was funded by Endo Pharmaceuticals. Dr. Peniston said he had no financial conflicts to disclose, but several study coauthors were employed by either Novartis or Endo.

Teen birth rates in the United States fell by 37% over the past two decades, reaching the lowest rate ever recorded, according to data from the Centers for Disease Control and Prevention.

Despite those promising data, "we still have a ways to go to improve our teen birth rate to reflect what is seen in other parts of the world," said Ursula Bauer, Ph.D., director of the National Center for Chronic Disease Prevention and Health Promotion, and Dr. Wanda Barfield, director of the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, in a teleconference.

The birth rate for girls aged 15-19 years in 2008 and 2009 was 39 per 1,000 girls in the United States, according to the report, which was published online April 5 in Morbidity and Mortality Weekly Report (MMWR 2011;60:1-8).

However, teen birth rates in the United States are as much as nine times higher than in many other developed countries. Teen birth rates for 2008-2009 were 27 per 1,000 in Great Britain, 10 per 1,000 in Germany and France, and 6 per 1,000 in Sweden and Denmark.

The researchers, from the Centers for Disease Control and Prevention (CDC), reviewed National Vital Statistics System data from 1991 to 2009 on teen birth rates, as well as National Youth Risk Behavior Survey data on sexual activity and contraceptive use. They also reviewed data on sex education and the use of reproductive health services for teens aged 15-19 years from the 2006-2008 National Survey of Family Growth.

In 2009, teen birth rates were lowest in the Northeastern and upper Midwestern states and highest in the Southern states. The states with the lowest birth rates – Connecticut, Massachusetts, New Hampshire, New Jersey, and Vermont – posted rates ranging from 16 to 23 births per 1,000 girls aged 15-19 years. The states with the highest rates – Arkansas, Mississippi, New Mexico, Oklahoma, and Texas – had rates ranging from 59 to 64 births per 1,000 girls aged 15-19 years.

The number of teens having sex declined across white, black, and Hispanic ethnicities for both boys and girls, but black and Hispanic girls remained at least twice as likely as white girls to become teen mothers.

Approximately 46% of teens in the United States have had sexual intercourse – down from 54% in 1991 – and 12% of those teens used no contraception, down from 16% in 1991, according to the report. In addition, approximately half of teens had spoken with parents about abstinence or birth control.

"Health care providers have a key role to play in bringing down teen birth rates and teen pregnancy rates," said Dr. Bauer. "Talking to teens, both boys and girls, about sexual health and reproductive health, and talking about available contraception, is very important for health care providers in their encounters with teens," she said.

According to a CDC fact sheet, health care providers can help reduce the teen birth rate in the United States by making more birth control options available to sexually active teens, including long-acting methods such as IUDs, and by educating teens about the proper use of birth control options, including condoms and oral contraceptives.

Teen birth rates in the United States fell by 37% over the past two decades, reaching the lowest rate ever recorded, according to data from the Centers for Disease Control and Prevention.

Despite those promising data, "we still have a ways to go to improve our teen birth rate to reflect what is seen in other parts of the world," said Ursula Bauer, Ph.D., director of the National Center for Chronic Disease Prevention and Health Promotion, and Dr. Wanda Barfield, director of the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, in a teleconference.

The birth rate for girls aged 15-19 years in 2008 and 2009 was 39 per 1,000 girls in the United States, according to the report, which was published online April 5 in Morbidity and Mortality Weekly Report (MMWR 2011;60:1-8).

However, teen birth rates in the United States are as much as nine times higher than in many other developed countries. Teen birth rates for 2008-2009 were 27 per 1,000 in Great Britain, 10 per 1,000 in Germany and France, and 6 per 1,000 in Sweden and Denmark.

The researchers, from the Centers for Disease Control and Prevention (CDC), reviewed National Vital Statistics System data from 1991 to 2009 on teen birth rates, as well as National Youth Risk Behavior Survey data on sexual activity and contraceptive use. They also reviewed data on sex education and the use of reproductive health services for teens aged 15-19 years from the 2006-2008 National Survey of Family Growth.

In 2009, teen birth rates were lowest in the Northeastern and upper Midwestern states and highest in the Southern states. The states with the lowest birth rates – Connecticut, Massachusetts, New Hampshire, New Jersey, and Vermont – posted rates ranging from 16 to 23 births per 1,000 girls aged 15-19 years. The states with the highest rates – Arkansas, Mississippi, New Mexico, Oklahoma, and Texas – had rates ranging from 59 to 64 births per 1,000 girls aged 15-19 years.

The number of teens having sex declined across white, black, and Hispanic ethnicities for both boys and girls, but black and Hispanic girls remained at least twice as likely as white girls to become teen mothers.

Approximately 46% of teens in the United States have had sexual intercourse – down from 54% in 1991 – and 12% of those teens used no contraception, down from 16% in 1991, according to the report. In addition, approximately half of teens had spoken with parents about abstinence or birth control.

"Health care providers have a key role to play in bringing down teen birth rates and teen pregnancy rates," said Dr. Bauer. "Talking to teens, both boys and girls, about sexual health and reproductive health, and talking about available contraception, is very important for health care providers in their encounters with teens," she said.

According to a CDC fact sheet, health care providers can help reduce the teen birth rate in the United States by making more birth control options available to sexually active teens, including long-acting methods such as IUDs, and by educating teens about the proper use of birth control options, including condoms and oral contraceptives.

Teen birth rates in the United States fell by 37% over the past two decades, reaching the lowest rate ever recorded, according to data from the Centers for Disease Control and Prevention.

Despite those promising data, "we still have a ways to go to improve our teen birth rate to reflect what is seen in other parts of the world," said Ursula Bauer, Ph.D., director of the National Center for Chronic Disease Prevention and Health Promotion, and Dr. Wanda Barfield, director of the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, in a teleconference.

The birth rate for girls aged 15-19 years in 2008 and 2009 was 39 per 1,000 girls in the United States, according to the report, which was published online April 5 in Morbidity and Mortality Weekly Report (MMWR 2011;60:1-8).

However, teen birth rates in the United States are as much as nine times higher than in many other developed countries. Teen birth rates for 2008-2009 were 27 per 1,000 in Great Britain, 10 per 1,000 in Germany and France, and 6 per 1,000 in Sweden and Denmark.

The researchers, from the Centers for Disease Control and Prevention (CDC), reviewed National Vital Statistics System data from 1991 to 2009 on teen birth rates, as well as National Youth Risk Behavior Survey data on sexual activity and contraceptive use. They also reviewed data on sex education and the use of reproductive health services for teens aged 15-19 years from the 2006-2008 National Survey of Family Growth.

In 2009, teen birth rates were lowest in the Northeastern and upper Midwestern states and highest in the Southern states. The states with the lowest birth rates – Connecticut, Massachusetts, New Hampshire, New Jersey, and Vermont – posted rates ranging from 16 to 23 births per 1,000 girls aged 15-19 years. The states with the highest rates – Arkansas, Mississippi, New Mexico, Oklahoma, and Texas – had rates ranging from 59 to 64 births per 1,000 girls aged 15-19 years.

The number of teens having sex declined across white, black, and Hispanic ethnicities for both boys and girls, but black and Hispanic girls remained at least twice as likely as white girls to become teen mothers.

Approximately 46% of teens in the United States have had sexual intercourse – down from 54% in 1991 – and 12% of those teens used no contraception, down from 16% in 1991, according to the report. In addition, approximately half of teens had spoken with parents about abstinence or birth control.

"Health care providers have a key role to play in bringing down teen birth rates and teen pregnancy rates," said Dr. Bauer. "Talking to teens, both boys and girls, about sexual health and reproductive health, and talking about available contraception, is very important for health care providers in their encounters with teens," she said.

According to a CDC fact sheet, health care providers can help reduce the teen birth rate in the United States by making more birth control options available to sexually active teens, including long-acting methods such as IUDs, and by educating teens about the proper use of birth control options, including condoms and oral contraceptives.

Teen birth rates in the United States fell by 37% over the past two decades, reaching the lowest rate ever recorded, according to data from the Centers for Disease Control and Prevention.

Despite those promising data, "we still have a ways to go to improve our teen birth rate to reflect what is seen in other parts of the world," said Ursula Bauer, Ph.D., director of the National Center for Chronic Disease Prevention and Health Promotion, and Dr. Wanda Barfield, director of the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, in a teleconference.

The birth rate for girls aged 15-19 years in 2008 and 2009 was 39 per 1,000 girls in the United States, according to the report, which was published online April 5 in Morbidity and Mortality Weekly Report (MMWR 2011;60:1-8).

However, teen birth rates in the United States are as much as nine times higher than in many other developed countries. Teen birth rates for 2008-2009 were 27 per 1,000 in Great Britain, 10 per 1,000 in Germany and France, and 6 per 1,000 in Sweden and Denmark.

The researchers, from the Centers for Disease Control and Prevention (CDC), reviewed National Vital Statistics System data from 1991 to 2009 on teen birth rates, as well as National Youth Risk Behavior Survey data on sexual activity and contraceptive use. They also reviewed data on sex education and the use of reproductive health services for teens aged 15-19 years from the 2006-2008 National Survey of Family Growth.

In 2009, teen birth rates were lowest in the Northeastern and upper Midwestern states and highest in the Southern states. The states with the lowest birth rates – Connecticut, Massachusetts, New Hampshire, New Jersey, and Vermont – posted rates ranging from 16 to 23 births per 1,000 girls aged 15-19 years. The states with the highest rates – Arkansas, Mississippi, New Mexico, Oklahoma, and Texas – had rates ranging from 59 to 64 births per 1,000 girls aged 15-19 years.

The number of teens having sex declined across white, black, and Hispanic ethnicities for both boys and girls, but black and Hispanic girls remained at least twice as likely as white girls to become teen mothers.

Approximately 46% of teens in the United States have had sexual intercourse – down from 54% in 1991 – and 12% of those teens used no contraception, down from 16% in 1991, according to the report. In addition, approximately half of teens had spoken with parents about abstinence or birth control.

"Health care providers have a key role to play in bringing down teen birth rates and teen pregnancy rates," said Dr. Bauer. "Talking to teens, both boys and girls, about sexual health and reproductive health, and talking about available contraception, is very important for health care providers in their encounters with teens," she said.

According to a CDC fact sheet, health care providers can help reduce the teen birth rate in the United States by making more birth control options available to sexually active teens, including long-acting methods such as IUDs, and by educating teens about the proper use of birth control options, including condoms and oral contraceptives.

Teen birth rates in the United States fell by 37% over the past two decades, reaching the lowest rate ever recorded, according to data from the Centers for Disease Control and Prevention.

Despite those promising data, "we still have a ways to go to improve our teen birth rate to reflect what is seen in other parts of the world," said Ursula Bauer, Ph.D., director of the National Center for Chronic Disease Prevention and Health Promotion, and Dr. Wanda Barfield, director of the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, in a teleconference.

The birth rate for girls aged 15-19 years in 2008 and 2009 was 39 per 1,000 girls in the United States, according to the report, which was published online April 5 in Morbidity and Mortality Weekly Report (MMWR 2011;60:1-8).

However, teen birth rates in the United States are as much as nine times higher than in many other developed countries. Teen birth rates for 2008-2009 were 27 per 1,000 in Great Britain, 10 per 1,000 in Germany and France, and 6 per 1,000 in Sweden and Denmark.

The researchers, from the Centers for Disease Control and Prevention (CDC), reviewed National Vital Statistics System data from 1991 to 2009 on teen birth rates, as well as National Youth Risk Behavior Survey data on sexual activity and contraceptive use. They also reviewed data on sex education and the use of reproductive health services for teens aged 15-19 years from the 2006-2008 National Survey of Family Growth.

In 2009, teen birth rates were lowest in the Northeastern and upper Midwestern states and highest in the Southern states. The states with the lowest birth rates – Connecticut, Massachusetts, New Hampshire, New Jersey, and Vermont – posted rates ranging from 16 to 23 births per 1,000 girls aged 15-19 years. The states with the highest rates – Arkansas, Mississippi, New Mexico, Oklahoma, and Texas – had rates ranging from 59 to 64 births per 1,000 girls aged 15-19 years.

The number of teens having sex declined across white, black, and Hispanic ethnicities for both boys and girls, but black and Hispanic girls remained at least twice as likely as white girls to become teen mothers.

Approximately 46% of teens in the United States have had sexual intercourse – down from 54% in 1991 – and 12% of those teens used no contraception, down from 16% in 1991, according to the report. In addition, approximately half of teens had spoken with parents about abstinence or birth control.

"Health care providers have a key role to play in bringing down teen birth rates and teen pregnancy rates," said Dr. Bauer. "Talking to teens, both boys and girls, about sexual health and reproductive health, and talking about available contraception, is very important for health care providers in their encounters with teens," she said.

According to a CDC fact sheet, health care providers can help reduce the teen birth rate in the United States by making more birth control options available to sexually active teens, including long-acting methods such as IUDs, and by educating teens about the proper use of birth control options, including condoms and oral contraceptives.

Teen birth rates in the United States fell by 37% over the past two decades, reaching the lowest rate ever recorded, according to data from the Centers for Disease Control and Prevention.

Despite those promising data, "we still have a ways to go to improve our teen birth rate to reflect what is seen in other parts of the world," said Ursula Bauer, Ph.D., director of the National Center for Chronic Disease Prevention and Health Promotion, and Dr. Wanda Barfield, director of the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, in a teleconference.

The birth rate for girls aged 15-19 years in 2008 and 2009 was 39 per 1,000 girls in the United States, according to the report, which was published online April 5 in Morbidity and Mortality Weekly Report (MMWR 2011;60:1-8).

However, teen birth rates in the United States are as much as nine times higher than in many other developed countries. Teen birth rates for 2008-2009 were 27 per 1,000 in Great Britain, 10 per 1,000 in Germany and France, and 6 per 1,000 in Sweden and Denmark.

The researchers, from the Centers for Disease Control and Prevention (CDC), reviewed National Vital Statistics System data from 1991 to 2009 on teen birth rates, as well as National Youth Risk Behavior Survey data on sexual activity and contraceptive use. They also reviewed data on sex education and the use of reproductive health services for teens aged 15-19 years from the 2006-2008 National Survey of Family Growth.

In 2009, teen birth rates were lowest in the Northeastern and upper Midwestern states and highest in the Southern states. The states with the lowest birth rates – Connecticut, Massachusetts, New Hampshire, New Jersey, and Vermont – posted rates ranging from 16 to 23 births per 1,000 girls aged 15-19 years. The states with the highest rates – Arkansas, Mississippi, New Mexico, Oklahoma, and Texas – had rates ranging from 59 to 64 births per 1,000 girls aged 15-19 years.

The number of teens having sex declined across white, black, and Hispanic ethnicities for both boys and girls, but black and Hispanic girls remained at least twice as likely as white girls to become teen mothers.

Approximately 46% of teens in the United States have had sexual intercourse – down from 54% in 1991 – and 12% of those teens used no contraception, down from 16% in 1991, according to the report. In addition, approximately half of teens had spoken with parents about abstinence or birth control.

"Health care providers have a key role to play in bringing down teen birth rates and teen pregnancy rates," said Dr. Bauer. "Talking to teens, both boys and girls, about sexual health and reproductive health, and talking about available contraception, is very important for health care providers in their encounters with teens," she said.

According to a CDC fact sheet, health care providers can help reduce the teen birth rate in the United States by making more birth control options available to sexually active teens, including long-acting methods such as IUDs, and by educating teens about the proper use of birth control options, including condoms and oral contraceptives.

Millions of Americans aged 65 years and older are not receiving potentially lifesaving preventive services, according to a report that was issued by the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services.

Approximately 85% of flu-related deaths and 63% of flu-related hospitalizations occur in adults aged 65 years and older.

Data have shown that use of the pneumococcal vaccine is a cost-effective way to improve survival and reduce hospital stays in older adults who have community-acquired pneumonia, according to the authors of the report, “Enhancing Use of Clinical Preventive Services Among Older Adults: Closing the Gap.”

However, in 2009, more than 31% of older adults had not received an influenza vaccination in the past year, while more than 33% reported that they had never received a pneumococcal vaccination.

The report included eight indicators to measure the use of clinical preventive health services by American adults aged 65 years and older: influenza vaccination; pneumococcal vaccination; counseling for smoking cessation; and screening for breast cancer, colorectal cancer, diabetes, lipid disorders, and osteoporosis.

Breast cancer screening and cholesterol screening were the most widely used services. Only 17% of women aged 65 years and older reported not receiving breast cancer screening in the past 2 years, while only 5% of adults aged 65 and older said that they had not had blood cholesterol screening in the past 5 years.

The report also highlighted ethnic disparities in many of the preventive services for older adults.

Approximately 49% of Asian/Pacific Islanders and 47% of Hispanics in the United States reported that they had not undergone colorectal cancer screening, compared with 37% of blacks, 35% of American Indians/Alaska Natives, and 34% of whites. In addition, approximately 51% of Hispanics, 47% of blacks and Asian/Pacific Islanders, and 36% of American Indians/Alaska Natives reported never receiving a pneumococcal vaccine, compared with 30% of whites.

The authors of the report recommended a number of interventions for improving preventive care among older adults, including promoting annual wellness visits, reducing barriers to preventive care services, and tailoring preventive health messages to the needs of each individual.

The report also recommended several additional preventive services that could be used by older adults: screening and counseling for alcohol misuse; zoster vaccination; aspirin use; blood pressure screening; cervical cancer screening; depression screening and counseling; and obesity screening and counseling.

The full report is now available online at http://www.cdc.gov/Features/PreventiveServices/

Millions of Americans aged 65 years and older are not receiving potentially lifesaving preventive services, according to a report that was issued by the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services.

Approximately 85% of flu-related deaths and 63% of flu-related hospitalizations occur in adults aged 65 years and older.

Data have shown that use of the pneumococcal vaccine is a cost-effective way to improve survival and reduce hospital stays in older adults who have community-acquired pneumonia, according to the authors of the report, “Enhancing Use of Clinical Preventive Services Among Older Adults: Closing the Gap.”

However, in 2009, more than 31% of older adults had not received an influenza vaccination in the past year, while more than 33% reported that they had never received a pneumococcal vaccination.

The report included eight indicators to measure the use of clinical preventive health services by American adults aged 65 years and older: influenza vaccination; pneumococcal vaccination; counseling for smoking cessation; and screening for breast cancer, colorectal cancer, diabetes, lipid disorders, and osteoporosis.

Breast cancer screening and cholesterol screening were the most widely used services. Only 17% of women aged 65 years and older reported not receiving breast cancer screening in the past 2 years, while only 5% of adults aged 65 and older said that they had not had blood cholesterol screening in the past 5 years.

The report also highlighted ethnic disparities in many of the preventive services for older adults.

Approximately 49% of Asian/Pacific Islanders and 47% of Hispanics in the United States reported that they had not undergone colorectal cancer screening, compared with 37% of blacks, 35% of American Indians/Alaska Natives, and 34% of whites. In addition, approximately 51% of Hispanics, 47% of blacks and Asian/Pacific Islanders, and 36% of American Indians/Alaska Natives reported never receiving a pneumococcal vaccine, compared with 30% of whites.

The authors of the report recommended a number of interventions for improving preventive care among older adults, including promoting annual wellness visits, reducing barriers to preventive care services, and tailoring preventive health messages to the needs of each individual.

The report also recommended several additional preventive services that could be used by older adults: screening and counseling for alcohol misuse; zoster vaccination; aspirin use; blood pressure screening; cervical cancer screening; depression screening and counseling; and obesity screening and counseling.

The full report is now available online at http://www.cdc.gov/Features/PreventiveServices/

Millions of Americans aged 65 years and older are not receiving potentially lifesaving preventive services, according to a report that was issued by the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services.

Approximately 85% of flu-related deaths and 63% of flu-related hospitalizations occur in adults aged 65 years and older.

Data have shown that use of the pneumococcal vaccine is a cost-effective way to improve survival and reduce hospital stays in older adults who have community-acquired pneumonia, according to the authors of the report, “Enhancing Use of Clinical Preventive Services Among Older Adults: Closing the Gap.”

However, in 2009, more than 31% of older adults had not received an influenza vaccination in the past year, while more than 33% reported that they had never received a pneumococcal vaccination.

The report included eight indicators to measure the use of clinical preventive health services by American adults aged 65 years and older: influenza vaccination; pneumococcal vaccination; counseling for smoking cessation; and screening for breast cancer, colorectal cancer, diabetes, lipid disorders, and osteoporosis.

Breast cancer screening and cholesterol screening were the most widely used services. Only 17% of women aged 65 years and older reported not receiving breast cancer screening in the past 2 years, while only 5% of adults aged 65 and older said that they had not had blood cholesterol screening in the past 5 years.

The report also highlighted ethnic disparities in many of the preventive services for older adults.

Approximately 49% of Asian/Pacific Islanders and 47% of Hispanics in the United States reported that they had not undergone colorectal cancer screening, compared with 37% of blacks, 35% of American Indians/Alaska Natives, and 34% of whites. In addition, approximately 51% of Hispanics, 47% of blacks and Asian/Pacific Islanders, and 36% of American Indians/Alaska Natives reported never receiving a pneumococcal vaccine, compared with 30% of whites.

The authors of the report recommended a number of interventions for improving preventive care among older adults, including promoting annual wellness visits, reducing barriers to preventive care services, and tailoring preventive health messages to the needs of each individual.

The report also recommended several additional preventive services that could be used by older adults: screening and counseling for alcohol misuse; zoster vaccination; aspirin use; blood pressure screening; cervical cancer screening; depression screening and counseling; and obesity screening and counseling.

The full report is now available online at http://www.cdc.gov/Features/PreventiveServices/

Major Finding: UPDRS motor scores improved a mean of 8.1 points in patients who received AAV2-GAD, which was significantly more than the 4.7-point improvement seen in patients who underwent a sham procedure.

Data Source: Phase II trial of 45 Parkinson's disease patients with UPDRS motor scores of 25 or greater.

Disclosures: Neurologix funded the trial. Many of the investigators reported serving as speakers or consultants to or receiving grant funding from many companies that manufacture treatments for Parkinson's disease. Dr. Hutchinson had no financial conflicts to disclose.

Direct infusion of the gene for glutamic acid decarboxylase into the subthalamic nucleus of patients with Parkinson's disease significantly improved measures of motor function, compared with patients who underwent a sham procedure, according to the results of a phase II trial in 45 patients.

The study was “the first successful randomized, double-blind gene therapy trial for a neurological disorder” and serves as a proof of concept for similar studies, justifying its continued development, Dr. Peter A. LeWitt of Wayne State University, Detroit, and his colleagues reported.

However, glutamic acid decarboxylase (GAD) gene therapy is not the only type of gene therapy under investigation for Parkinson's disease. A separate phase II trial with the gene for the neurotrophic factor neurturin is now enrolling patients.

In the study conducted by Dr. LeWitt and his associates, 22 Parkinson's patients with Unified Parkinson's Disease Rating Scale (UPDRS) motor scores of 25 or more were randomized to gene therapy and 23 were randomized to sham surgery. The gene therapy involved inserting the GAD gene into the subthalamic nucleus using the adeno-associated viral vector, AAV2.

GAD is the rate-limiting enzyme for the neurotransmitter gamma-aminobutyric acid (GABA). The destruction of nigrostriatal dopaminergic neurons in Parkinson's disease alters the dynamics of inhibitory GABA input to the subthalamic nucleus, which worsens parkinsonian symptoms. Improvement of symptoms has been shown previously with infusions of a GABA agonist into the subthalamic nucleus of Parkinson's disease patients during surgery for deep brain stimulation and also in animal models of parkinsonism.

After 6 months, patients in the AAV2-GAD group showed a 23% improvement (an average 8.1-point decrease) in UPDRS scores in the “off” state (while not on medications), compared with a 13% improvement (an average 4.7-point decrease) in the sham group (Lancet Neurol. 2011 March 17 [doi:10.1016/S1474-4422(11)70039-4]).

“The change of UPDRS scores from baseline differed significantly between treatment groups across all three postoperative time points” at 1, 3, and 6 months, the researchers noted.

The only severe adverse event reported during the study period was a case of bowel obstruction in the AAV2-GAD group. Mild and moderate adverse events included headaches and nausea.

In addition, the investigator's clinical global impression of Parkinson's disease severity improved significantly from baseline to 6 months in the treatment group vs. the sham group (3.4 vs. 3.9).

The patients' ages ranged from 30 to 75 years. A total of 6 patients in the treatment group and 2 in the sham group did not receive the complete intervention, leaving efficacy groups of 16 and 21, respectively.

The findings were limited by the study's small size and the possibility of inadequate blinding of the procedures because the patients were awake during their surgeries. However, “it is unlikely that the benefits in the AAV2-GAD treatment group were caused by the temporary placement of catheters in the subthalamic nucleus rather than from the infusion of the gene product,” the researchers wrote.

Although the study findings are promising, questions remain as to how long the effects of the gene therapy will last and what advantages it might have over deep brain stimulation, Dr. Michael Hutchinson of New York University, wrote in an accompanying editorial. The added value of the study is that the placebo effect is not large enough to explain the benefits of gene therapy seen in open-label surgical trials, he said (Lancet Neurol. 2011 March 17 [doi:10.1016/S1474-4422(11)70041-2]).

A separate investigational gene therapy treatment for Parkinson's disease, called CERE-120, proved to be safe but lacked efficacy in a recent randomized, sham-controlled, phase II trial that was sponsored by Ceregene Inc. (Lancet Neurol. 2010;9:1164-72). The investigators of that trial blamed its results on the failed delivery of the therapy (consisting of the AAV2 viral vector and the gene for neurturin, a member of the same protein family as glial-derived neurotrophic factor) to dopaminergic neurons.

In the trial, AAV2-neurturin was injected into an area of the brain called the putamen in patients with Parkinson's disease, where the nerve terminals of degenerating dopaminergic neurons reside. However, the investigators realized that neurturin was not being transported effectively to the cell bodies of the dopaminergic neurons, which reside in the substantia nigra (Mov. Disord. 2011;26:27-36).

A new treatment protocol that delivers a larger dose of AAV2-neurturin to the putamen, as well as directly to the substantia nigra, is currently being tested in a new randomized, sham-controlled, phase II trial of approximately 52 Parkinson's disease patients at 11 U.S. centers. The new treatment protocol was successfully given to six patients with Parkinson's disease in a phase I trial and has not been associated with any serious adverse events after 7-13 months of follow-up, according to Ceregene.

The new phase II trial of AAV2-neurturin is partially funded by the Michael J. Fox Foundation.

Jeff Evans contributed to this report.

Major Finding: UPDRS motor scores improved a mean of 8.1 points in patients who received AAV2-GAD, which was significantly more than the 4.7-point improvement seen in patients who underwent a sham procedure.

Data Source: Phase II trial of 45 Parkinson's disease patients with UPDRS motor scores of 25 or greater.

Disclosures: Neurologix funded the trial. Many of the investigators reported serving as speakers or consultants to or receiving grant funding from many companies that manufacture treatments for Parkinson's disease. Dr. Hutchinson had no financial conflicts to disclose.

Direct infusion of the gene for glutamic acid decarboxylase into the subthalamic nucleus of patients with Parkinson's disease significantly improved measures of motor function, compared with patients who underwent a sham procedure, according to the results of a phase II trial in 45 patients.

The study was “the first successful randomized, double-blind gene therapy trial for a neurological disorder” and serves as a proof of concept for similar studies, justifying its continued development, Dr. Peter A. LeWitt of Wayne State University, Detroit, and his colleagues reported.

However, glutamic acid decarboxylase (GAD) gene therapy is not the only type of gene therapy under investigation for Parkinson's disease. A separate phase II trial with the gene for the neurotrophic factor neurturin is now enrolling patients.

In the study conducted by Dr. LeWitt and his associates, 22 Parkinson's patients with Unified Parkinson's Disease Rating Scale (UPDRS) motor scores of 25 or more were randomized to gene therapy and 23 were randomized to sham surgery. The gene therapy involved inserting the GAD gene into the subthalamic nucleus using the adeno-associated viral vector, AAV2.

GAD is the rate-limiting enzyme for the neurotransmitter gamma-aminobutyric acid (GABA). The destruction of nigrostriatal dopaminergic neurons in Parkinson's disease alters the dynamics of inhibitory GABA input to the subthalamic nucleus, which worsens parkinsonian symptoms. Improvement of symptoms has been shown previously with infusions of a GABA agonist into the subthalamic nucleus of Parkinson's disease patients during surgery for deep brain stimulation and also in animal models of parkinsonism.

After 6 months, patients in the AAV2-GAD group showed a 23% improvement (an average 8.1-point decrease) in UPDRS scores in the “off” state (while not on medications), compared with a 13% improvement (an average 4.7-point decrease) in the sham group (Lancet Neurol. 2011 March 17 [doi:10.1016/S1474-4422(11)70039-4]).

“The change of UPDRS scores from baseline differed significantly between treatment groups across all three postoperative time points” at 1, 3, and 6 months, the researchers noted.

The only severe adverse event reported during the study period was a case of bowel obstruction in the AAV2-GAD group. Mild and moderate adverse events included headaches and nausea.

In addition, the investigator's clinical global impression of Parkinson's disease severity improved significantly from baseline to 6 months in the treatment group vs. the sham group (3.4 vs. 3.9).

The patients' ages ranged from 30 to 75 years. A total of 6 patients in the treatment group and 2 in the sham group did not receive the complete intervention, leaving efficacy groups of 16 and 21, respectively.

The findings were limited by the study's small size and the possibility of inadequate blinding of the procedures because the patients were awake during their surgeries. However, “it is unlikely that the benefits in the AAV2-GAD treatment group were caused by the temporary placement of catheters in the subthalamic nucleus rather than from the infusion of the gene product,” the researchers wrote.

Although the study findings are promising, questions remain as to how long the effects of the gene therapy will last and what advantages it might have over deep brain stimulation, Dr. Michael Hutchinson of New York University, wrote in an accompanying editorial. The added value of the study is that the placebo effect is not large enough to explain the benefits of gene therapy seen in open-label surgical trials, he said (Lancet Neurol. 2011 March 17 [doi:10.1016/S1474-4422(11)70041-2]).

A separate investigational gene therapy treatment for Parkinson's disease, called CERE-120, proved to be safe but lacked efficacy in a recent randomized, sham-controlled, phase II trial that was sponsored by Ceregene Inc. (Lancet Neurol. 2010;9:1164-72). The investigators of that trial blamed its results on the failed delivery of the therapy (consisting of the AAV2 viral vector and the gene for neurturin, a member of the same protein family as glial-derived neurotrophic factor) to dopaminergic neurons.

In the trial, AAV2-neurturin was injected into an area of the brain called the putamen in patients with Parkinson's disease, where the nerve terminals of degenerating dopaminergic neurons reside. However, the investigators realized that neurturin was not being transported effectively to the cell bodies of the dopaminergic neurons, which reside in the substantia nigra (Mov. Disord. 2011;26:27-36).

A new treatment protocol that delivers a larger dose of AAV2-neurturin to the putamen, as well as directly to the substantia nigra, is currently being tested in a new randomized, sham-controlled, phase II trial of approximately 52 Parkinson's disease patients at 11 U.S. centers. The new treatment protocol was successfully given to six patients with Parkinson's disease in a phase I trial and has not been associated with any serious adverse events after 7-13 months of follow-up, according to Ceregene.

The new phase II trial of AAV2-neurturin is partially funded by the Michael J. Fox Foundation.

Jeff Evans contributed to this report.

Major Finding: UPDRS motor scores improved a mean of 8.1 points in patients who received AAV2-GAD, which was significantly more than the 4.7-point improvement seen in patients who underwent a sham procedure.

Data Source: Phase II trial of 45 Parkinson's disease patients with UPDRS motor scores of 25 or greater.

Disclosures: Neurologix funded the trial. Many of the investigators reported serving as speakers or consultants to or receiving grant funding from many companies that manufacture treatments for Parkinson's disease. Dr. Hutchinson had no financial conflicts to disclose.

Direct infusion of the gene for glutamic acid decarboxylase into the subthalamic nucleus of patients with Parkinson's disease significantly improved measures of motor function, compared with patients who underwent a sham procedure, according to the results of a phase II trial in 45 patients.

The study was “the first successful randomized, double-blind gene therapy trial for a neurological disorder” and serves as a proof of concept for similar studies, justifying its continued development, Dr. Peter A. LeWitt of Wayne State University, Detroit, and his colleagues reported.

However, glutamic acid decarboxylase (GAD) gene therapy is not the only type of gene therapy under investigation for Parkinson's disease. A separate phase II trial with the gene for the neurotrophic factor neurturin is now enrolling patients.

In the study conducted by Dr. LeWitt and his associates, 22 Parkinson's patients with Unified Parkinson's Disease Rating Scale (UPDRS) motor scores of 25 or more were randomized to gene therapy and 23 were randomized to sham surgery. The gene therapy involved inserting the GAD gene into the subthalamic nucleus using the adeno-associated viral vector, AAV2.

GAD is the rate-limiting enzyme for the neurotransmitter gamma-aminobutyric acid (GABA). The destruction of nigrostriatal dopaminergic neurons in Parkinson's disease alters the dynamics of inhibitory GABA input to the subthalamic nucleus, which worsens parkinsonian symptoms. Improvement of symptoms has been shown previously with infusions of a GABA agonist into the subthalamic nucleus of Parkinson's disease patients during surgery for deep brain stimulation and also in animal models of parkinsonism.

After 6 months, patients in the AAV2-GAD group showed a 23% improvement (an average 8.1-point decrease) in UPDRS scores in the “off” state (while not on medications), compared with a 13% improvement (an average 4.7-point decrease) in the sham group (Lancet Neurol. 2011 March 17 [doi:10.1016/S1474-4422(11)70039-4]).

“The change of UPDRS scores from baseline differed significantly between treatment groups across all three postoperative time points” at 1, 3, and 6 months, the researchers noted.

The only severe adverse event reported during the study period was a case of bowel obstruction in the AAV2-GAD group. Mild and moderate adverse events included headaches and nausea.

In addition, the investigator's clinical global impression of Parkinson's disease severity improved significantly from baseline to 6 months in the treatment group vs. the sham group (3.4 vs. 3.9).

The patients' ages ranged from 30 to 75 years. A total of 6 patients in the treatment group and 2 in the sham group did not receive the complete intervention, leaving efficacy groups of 16 and 21, respectively.

The findings were limited by the study's small size and the possibility of inadequate blinding of the procedures because the patients were awake during their surgeries. However, “it is unlikely that the benefits in the AAV2-GAD treatment group were caused by the temporary placement of catheters in the subthalamic nucleus rather than from the infusion of the gene product,” the researchers wrote.

Although the study findings are promising, questions remain as to how long the effects of the gene therapy will last and what advantages it might have over deep brain stimulation, Dr. Michael Hutchinson of New York University, wrote in an accompanying editorial. The added value of the study is that the placebo effect is not large enough to explain the benefits of gene therapy seen in open-label surgical trials, he said (Lancet Neurol. 2011 March 17 [doi:10.1016/S1474-4422(11)70041-2]).

A separate investigational gene therapy treatment for Parkinson's disease, called CERE-120, proved to be safe but lacked efficacy in a recent randomized, sham-controlled, phase II trial that was sponsored by Ceregene Inc. (Lancet Neurol. 2010;9:1164-72). The investigators of that trial blamed its results on the failed delivery of the therapy (consisting of the AAV2 viral vector and the gene for neurturin, a member of the same protein family as glial-derived neurotrophic factor) to dopaminergic neurons.

In the trial, AAV2-neurturin was injected into an area of the brain called the putamen in patients with Parkinson's disease, where the nerve terminals of degenerating dopaminergic neurons reside. However, the investigators realized that neurturin was not being transported effectively to the cell bodies of the dopaminergic neurons, which reside in the substantia nigra (Mov. Disord. 2011;26:27-36).

A new treatment protocol that delivers a larger dose of AAV2-neurturin to the putamen, as well as directly to the substantia nigra, is currently being tested in a new randomized, sham-controlled, phase II trial of approximately 52 Parkinson's disease patients at 11 U.S. centers. The new treatment protocol was successfully given to six patients with Parkinson's disease in a phase I trial and has not been associated with any serious adverse events after 7-13 months of follow-up, according to Ceregene.

The new phase II trial of AAV2-neurturin is partially funded by the Michael J. Fox Foundation.

Jeff Evans contributed to this report.

Millions of Americans aged 65 years and older are not receiving potentially lifesaving preventive services, according to a report issued by the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services.

About 85% of flu-related deaths and 63% of flu-related hospitalizations occur in adults aged 65 years and older. Data have shown that the pneumococcal vaccine is a cost-effective way to improve survival and reduce hospital stay in older adults with community-acquired pneumonia, wrote the authors of the report, “Enhancing Use of Clinical Preventive Services Among Older Adults: Closing the Gap.”

However, in 2009, more than 31% of older adults had not received an influenza vaccination in the past year, while more than 33% reported that they had never received a pneumococcal vaccination.

The report included eight indicators to measure the use of clinical preventive health services by U.S. adults aged 65 years and older: influenza vaccination; pneumococcal vaccination; counseling for smoking cessation; and screening for breast cancer, colorectal cancer, diabetes, lipid disorders, and osteoporosis.

Breast cancer screening and cholesterol screening were the most widely used services. Only 17% of women aged 65 and older reported not receiving breast cancer screening in the past 2 years, while only 5% of adults in this age group said they had not had blood cholesterol screening in the past 5 years.

The report also highlighted ethnic disparities in many of the preventive services for older adults. Approximately 49% of Asian/Pacific Islanders and 47% of Hispanics in the United States reported that they had not undergone colorectal cancer screening, compared with 37% of blacks, 35% of American Indians/Alaska Natives, and 34% of whites. About 51% of Hispanics, 47% of blacks and Asian/Pacific Islanders, and 36% of American Indians/Alaska Natives reported never receiving a pneumococcal vaccine, compared with 30% of whites.

The report recommended interventions such as promoting annual wellness visits, reducing barriers to preventive care services, and tailoring preventive health messages to the needs of each individual. Screening and counseling for alcohol misuse, zoster vaccination, aspirin use, blood pressure, cervical cancer, depression, and obesity also are recommended.

To view the full report, go to www.cdc.gov/Features/PreventiveServices

Millions of Americans aged 65 years and older are not receiving potentially lifesaving preventive services, according to a report issued by the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services.

About 85% of flu-related deaths and 63% of flu-related hospitalizations occur in adults aged 65 years and older. Data have shown that the pneumococcal vaccine is a cost-effective way to improve survival and reduce hospital stay in older adults with community-acquired pneumonia, wrote the authors of the report, “Enhancing Use of Clinical Preventive Services Among Older Adults: Closing the Gap.”

However, in 2009, more than 31% of older adults had not received an influenza vaccination in the past year, while more than 33% reported that they had never received a pneumococcal vaccination.

The report included eight indicators to measure the use of clinical preventive health services by U.S. adults aged 65 years and older: influenza vaccination; pneumococcal vaccination; counseling for smoking cessation; and screening for breast cancer, colorectal cancer, diabetes, lipid disorders, and osteoporosis.

Breast cancer screening and cholesterol screening were the most widely used services. Only 17% of women aged 65 and older reported not receiving breast cancer screening in the past 2 years, while only 5% of adults in this age group said they had not had blood cholesterol screening in the past 5 years.

The report also highlighted ethnic disparities in many of the preventive services for older adults. Approximately 49% of Asian/Pacific Islanders and 47% of Hispanics in the United States reported that they had not undergone colorectal cancer screening, compared with 37% of blacks, 35% of American Indians/Alaska Natives, and 34% of whites. About 51% of Hispanics, 47% of blacks and Asian/Pacific Islanders, and 36% of American Indians/Alaska Natives reported never receiving a pneumococcal vaccine, compared with 30% of whites.

The report recommended interventions such as promoting annual wellness visits, reducing barriers to preventive care services, and tailoring preventive health messages to the needs of each individual. Screening and counseling for alcohol misuse, zoster vaccination, aspirin use, blood pressure, cervical cancer, depression, and obesity also are recommended.

To view the full report, go to www.cdc.gov/Features/PreventiveServices

Millions of Americans aged 65 years and older are not receiving potentially lifesaving preventive services, according to a report issued by the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services.

About 85% of flu-related deaths and 63% of flu-related hospitalizations occur in adults aged 65 years and older. Data have shown that the pneumococcal vaccine is a cost-effective way to improve survival and reduce hospital stay in older adults with community-acquired pneumonia, wrote the authors of the report, “Enhancing Use of Clinical Preventive Services Among Older Adults: Closing the Gap.”

However, in 2009, more than 31% of older adults had not received an influenza vaccination in the past year, while more than 33% reported that they had never received a pneumococcal vaccination.

The report included eight indicators to measure the use of clinical preventive health services by U.S. adults aged 65 years and older: influenza vaccination; pneumococcal vaccination; counseling for smoking cessation; and screening for breast cancer, colorectal cancer, diabetes, lipid disorders, and osteoporosis.

Breast cancer screening and cholesterol screening were the most widely used services. Only 17% of women aged 65 and older reported not receiving breast cancer screening in the past 2 years, while only 5% of adults in this age group said they had not had blood cholesterol screening in the past 5 years.

The report also highlighted ethnic disparities in many of the preventive services for older adults. Approximately 49% of Asian/Pacific Islanders and 47% of Hispanics in the United States reported that they had not undergone colorectal cancer screening, compared with 37% of blacks, 35% of American Indians/Alaska Natives, and 34% of whites. About 51% of Hispanics, 47% of blacks and Asian/Pacific Islanders, and 36% of American Indians/Alaska Natives reported never receiving a pneumococcal vaccine, compared with 30% of whites.

The report recommended interventions such as promoting annual wellness visits, reducing barriers to preventive care services, and tailoring preventive health messages to the needs of each individual. Screening and counseling for alcohol misuse, zoster vaccination, aspirin use, blood pressure, cervical cancer, depression, and obesity also are recommended.

To view the full report, go to www.cdc.gov/Features/PreventiveServices